Natalizumab treatment were 3.22 in the UK and 2.85 globally. Mean baseline Expanded Disability Status Scale (EDSS) scores were 4.2 in the UK and 3.5 globally. Median Multiple Sclerosis Severity Scores (MSSS) were 6.2 in the UK versus 4.9 globally (p<0.0001). Compared with the year prior to natalizumab initiation, on-treatment ARR decreased by 87% in the UK (P<0.0001) and by 88% globally (P<0.0001).

Conclusions The UK Cohort appears to have more aggressive disease, as evidenced by higher MSS score and higher ARR history. Despite this similar significant reductions in ARR were observed in the UK-specific and global cohorts.

Supported by Biogen Idec Ltd.
RN: grant support and support for travel to conferences from Biogen Idec Ltd.
JH: employee of Biogen Idec Ltd.